Andres, Martin (2018). Die Ablösung der klassischen Zytostatika durch BCL-2- und BCR-Inhibitoren geht in die nächste Runde. Leading Opinions. Hämatologie & Onkologie, 14(1), pp. 28-30. Universimed
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
LO_onko_1801_MA.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (4MB) |
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory |
UniBE Contributor: |
Andres, Martin |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1991-2838 |
Publisher: |
Universimed |
Language: |
German |
Submitter: |
Pierrette Durand Lüthi |
Date Deposited: |
27 Feb 2019 16:10 |
Last Modified: |
05 Dec 2022 15:25 |
BORIS DOI: |
10.7892/boris.125170 |
URI: |
https://boris.unibe.ch/id/eprint/125170 |
Actions (login required)
 |
Edit item |